Genomic Biomarker Market Poised To Garner High Revenues Owing To Increasing Demand For Personalized Medicine
The genomic biomarker market involves products and services associated with the use of genomic biomarkers for various applications including diagnostic and therapeutic development, drug discovery and development, personalized medicine, nutrigenomics, and others. Genomic biomarkers find widespread use in the identification of responsiveness to a particular drug or drug class, efficacy, potential risks of severe adverse effects, and other treatment-related information. It helps in disease risk assessment and early detection besides assisting in disease management and monitoring treatment response.
The Global Genomic Biomarker Market is estimated to be valued at US$ 6,072.92 Million in 2024 and is expected to exhibit a CAGR Of 7.1% over the forecast period 2024 To 2030.
Key Takeaways
Key players operating in the genomic biomarker market are Varian Medical Systems, Elekta AB, Becton, Dickinson and Company, IsoRay, Inc., Eckert & Ziegler BEBIG, and iCAD. Varian Medical Systems is one of the leading players providing cancer care solutions and has a strong presence in the radiation oncology market. Elekta AB offers radiation therapy solutions for treating cancer and brain disorders.
The growing demand for personalized medicine and non-invasive risk assessment techniques along with increasing applications of genomic biomarkers in drug discovery offer lucrative opportunities for market players. The market is witnessing increased collaborations between biotech and diagnostic companies to develop innovative biomarker-based diagnostic tests.
With technological advancements, players are focusing on expanding their geographical footprint to address the rising demand from emerging economies in Asia Pacific, Latin America, Middle East, and Africa. Furthermore, companies are investing in biomarker research programs to strengthen their product portfolio.
Market Drivers
Growing preference for personalized medicine is a key factor driving the genomic biomarker market. Genomic biomarkers help identify the most suitable treatment options and develop precision treatment plans for patients. With the rising burden of chronic diseases, the demand for innovative diagnostic and therapeutic solutions is increasing significantly. This is positively impacting the adoption of genomic biomarkers.
Market Restraints
High costs associated with biomarker-based tests and lack of comprehensive reimbursement policies in certain countries pose challenges to market growth. Setting up biomarker testing infrastructure requires massive capital investments. Additionally, the complexity of genomic data analysis and bioinformatics challenges hinder the widespread clinical adoption of genomic biomarkers. Stringent regulatory guidelines for companion diagnostic approval also restrain market expansion.
Segment Analysis
The global genomic biomarker market can be segmented based on prophylactic and prognostic testing. Prophylactic testing sub segment dominates the market as it plays a crucial role in evaluating the disease risk before the onset of symptoms. This helps in early detection of disease and allows physicians to design effective treatment and management plans. Prophylactic testing evaluates hereditary risk factors by looking at DNA, RNA, proteins or other molecules and is helpful in oncology, cardiology, and neurological diseases.
Regional Analysis
North America dominates the Global Genomic Biomarker Market and is expected to continue its dominance during the forecast period. This is attributed to the rising cancer prevalence, increasing demand for personalized medicine, growing focus on pharmacogenomics, and technological advancements in genomics. Asia Pacific is expected to be the fastest growing region owing to factors such as increasing healthcare awareness, rising funding for genomic research, growing incidents of cancer. Further, expanding pharmaceutical industry and improving healthcare infrastructure in emerging Asian countries provides growth opportunities in this region.
Get more insights on this topic :